This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1531003507313214v1 20/1/38    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wittgen, C. M. Search for Related Content PubMed PubMed Citation Articles by Wittgen, C. M. Pubmed/NCBI databases Medline Plus Health Information Peripheral Arterial Disease Social Bookmarking                         What's this?

Limb Ischemia: Medical Therapy Trial Update

Saint Louis University

^* To whom correspondence should be addressed. E-mail: wittgenc{at}slu.edu.

	Abstract

Peripheral arterial disease has a significant impact on the quality of a patient’s life. Pain, fear of limb loss, increased inactivity, and poor lifestyle choices such as continued smoking further debilitate these patients. Surgical and endovascular procedures have affected this outcome for many but carry the added risk of procedural complications and mortality for this group of high-risk individuals. Risk factor management and medical therapy carry little risk and can also improve functional outcome for many of these patients. Despite this, there are currently only two FDA-approved medications for the treatment of claudication. This review discusses published data on the impact of walking distance with investigational pharmacotherapy.

First published on April 2, 2008, doi:10.1177/1531003507313214

Perspectives in Vascular Surgery and Endovascular Therapy 2008;20:38.

A more recent version of this article appeared on March 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?